This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sandford, J. J. Articles by Nutt, D. J. Search for Related Content PubMed PubMed Citation Articles by Sandford, J. J. Articles by Nutt, D. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Panic Disorder Social Bookmarking                         What's this?

Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder

Psychopharmacology Unit, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, UK; john.j.sandford{at}ukgateway.net

S. Forshall

C. Bell

S. Argyropoulos

A. Rich

Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol, UK

K. J. D'Orlando

Addiction Therapies Inc., Wayland, MA, USA

R. E. Gammans

Incara Pharmaceuticals Inc., Research Triangle Park, NC, USA

D. J. Nutt

Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol, UK

Pagoclone is a cyclopyrrolone that is believed to act as a partial agonist at the -aminobutyric acid (GABA) A/benzodiazepine (BDZ) receptor. In theory, such partial agonists should be anxiolytic but lack the adverse side-effects of sedation, tolerance and withdrawal associated with full GABA-A/BDZ agonists. The objective of the randomized double-blind crossover study was to assess whether pagoclone was an effective anti-panic agent and also to assess its side-effect profile. Patients recruited had a diagnosis of Panic Disorder (DSM-IV) with at least one panic attack per week. Following a 2-week screening period, patients entered a 6-week trial consisting of two 2-week treatment periods, each followed by a 1-week washout. Patients were randomly assigned to receive either pagoclone 0.1 mg t.d.s. or placebo on their first treatment period and the converse on their second. The primary measure was daily panic attack dairy. Fourteen patients completed the study, the mean number of panic attacks during screening was 5.8 ± 0.8 (SEM), this fell to 3.6 ± 0.5 during treatment with pagoclone (p = 0.05) and 4.3 ± 0.8 with placebo (p = 0.14). There was no significant difference on direct comparison of pagoclone with placebo or in any of the secondary measures (including Rickels withdrawal scale) or the adverse event profiles. The study provides preliminary evidence that pagoclone has anxiolytic properties in the absence of typical BDZ side-effects. This is consistent with its theoretical mode of action as a partial agonist at the GABAA/BDZ receptor.

Key Words: GABA • pagoclone • panic disorder • partial agonist

Journal of Psychopharmacology, Vol. 15, No. 3, 205-208 (2001)
DOI: 10.1177/026988110101500312


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?